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Candida glabrata bloodstream infection (BSI) isolates from a particular geographic area
have been reported to comprise a relatively small number of the major sequence types
(STs) by multilocus sequence typing (MLST) analysis. Yet little is known about the
characteristics of major ST strains of C. glabrata. To address this question in Korea,
we investigated antifungal resistance and non-synonymous mutations of the mismatch
repair gene (msh2 mutations) in C. glabrata BSI isolates, as well as associated clinical
characteristics, and compared the results according to MLST genotype. We assessed
a total of 209 C. glabrata BSI isolates from seven hospitals in Korea for 2 years
(2009 and 2014). Clinical features of candidemia and their outcomes were analyzed
for 185 available cases. According to MLST, ST7 (47.8%) was the most common type,
followed by ST3 (22.5%); the remainder represented 28 types of minor STs (29.7%).
Fluconazole-resistance (FR) rates for ST7, ST3, and other strains were 9.0% (9/100),
8.5% (4/47), and 4.8% (3/62), respectively, and all were susceptible to amphotericin
B and micafungin. All ST7 isolates harbored the V239L mutation in msh2, known to
confer hypermutability, while 91.5% of ST3 isolates did not harbor the msh2 mutation.
Overall, isolates of the same ST had identical msh2 mutations, with the exception of nine
isolates. The msh2 mutations were identified in 68.8% (11/16) of the FR isolates and
67.4% (130/193) of the fluconazole susceptible-dose dependent isolates. There was no
significant difference in all clinical characteristics between ST3 and ST7. However, the
30-day mortality of C. glabrata candidemia due to the two major ST (ST3 or ST7) strains
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was significantly higher than that of candidemia due to other minor ST strains (45.1 vs.
25.0%, p < 0.05). Multivariate logistic regression analysis also showed that two major
STs (ST3 and ST7) were independent predictors of 30-day mortality. This study showed
for the first time that two STs (ST7 and ST3) were predominant among BSI isolates in
Korea, and that C. glabrata BSI isolates belonging to two major MLST genotypes are
characterized by higher mortality. In addition, most msh2 mutations align with MLST
genotype, irrespective of FR.
Keywords: Candida glabrata, MLST, MSH2, antifungal resistance, candidemia, mortality
INTRODUCTION
Candida glabrata is a commensal yeast in the human
gastrointestinal tract, genitourinary tract, or oral cavity, but
can cause serious bloodstream infections (BSI) in hospitalized
patients. Compared with other common Candida species,
C. glabrata has intrinsically low susceptibility to azole drugs,
especially to fluconazole, but it can develop antifungal resistance
rapidly in response to exposure to azoles or echinocandins
(Pfaller et al., 2003; Barberino et al., 2006; Jensen et al.,
2015). The frequency of BSI due to C. glabrata has increased
significantly over the past two decades, and C. glabrata has
become the second most commonly isolated bloodstream fungal
pathogen in Europe and North America, with 10–30% of isolates
being fluconazole resistant (FR) (Pfaller et al., 2007). However,
geographic variation has been observed in both the frequency of
isolation and fluconazole resistance among C. glabrata (Pfaller
et al., 2010). C. glabrata is the fourth most common cause of
candidemia, accounting for 14.2% of all cases of candidemia
in Korea, and the incidence of C. glabrata candidemia and
fluconazole resistance varies among hospitals (Won et al., 2015).
Although the use of fluconazole is associated with an increased
risk of BSIs caused by C. glabrata (Chow et al., 2008; Jensen
et al., 2015; Won et al., 2015), many questions regarding the
epidemiology of C. glabrata BSI remain unanswered (Lott et al.,
2010).
Candida glabrata is a haploid organism in which a single
DNA repair mutation is sufficient to cause an associated mutator
phenotype and subsequent emergence of resistance-conferring
mutations (Healey et al., 2016b). A recent study suggested
that elevated levels of both triazole and multi-drug resistance
associated with C. glabrata are at least partially due to the
presence of loss-of-function mutations in the mismatch repair
gene (msh2 mutations) (Healey et al., 2016b). Other factors may
also play a role, especially in the setting of low echinocandin
and polyene resistance, as reported in France, where fluconazole
resistance was not associated with the MSH2 genotype pointing
to other potential underlying factors (Dellière et al., 2016). Yet,
genotype and MSH2 status can be an important factor, as a recent
multilocus sequence typing (MLST) study of clinical C. glabrata
strains showed that different sequence types (STs) may carry
different msh2 alleles, suggesting that some determinants of drug
resistance or virulence may also vary among STs (Healey et al.,
2016a). MLST studies of C. glabrata BSI isolates conducted in the
United States or China have indicated that C. glabrata BSI isolates
comprise a relatively small number of the major STs, although
these major STs may vary geographically (Lott et al., 2010, 2012;
Hou et al., 2017). It is possible that major ST strains of C. glabrata
possess higher virulence traits to cause BSIs than do other isolates,
or different clinical characteristics. Until now, few studies have
evaluated the microbiological and clinical characteristics of major
ST strains of C. glabrata from a multicenter BSI surveillance
study. The objectives of this study were to detect the major MLST
genotypes among C. glabrata BSI isolates in Korean hospitals, and
to evaluate whether C. glabrata BSI strains belonging to the major
MLST genotypes have different clinical characteristics, and they
display different rates of antifungal resistance or msh2 mutations.
MATERIALS AND METHODS
Microorganisms
A total of 209 non-duplicate isolates of C. glabrata recovered
from blood cultures were included in this study. These isolates
were recovered from seven Korean university hospitals during
nationwide surveillance studies. Of the 209 BSI isolates, 94 were
collected from September 2009 to August 2010 (period 1), and
115 were collected from January to December 2014 (period 2). All
isolates were collected from blood cultures by routine methods
in use in each laboratory. All C. glabrata isolates were submitted
to Chonnam National University Hospital for testing. Species
identification was based on colony morphology on CHROMagar
Candida (BBL, Becton Dickinson, Sparks, MD, United States)
at 35◦C, and a commercial identification system (API 20C;
bioMérieux, Marcy L’Etoile, France, or the Vitek 2 system; Vitek
2 ID-YST, bioMérieux). The isolates which did not belong to
common STs in this study were re-identified by sequencing
of the internal transcribed spacer (ITS) of ribosomal DNA
and matrix-assisted laser desorption/ionization-time of flight
mass spectrometry (MALDI–TOF Biotyper, Bruker Daltonics,
Billerica, MA, United States) to differentiate from cryptic species
within the C. glabrata complex (Lee et al., 2017). All isolates were
confirmed as C. glabrata.
Antifungal Susceptibility Testing
In vitro testing of susceptibility to fluconazole, voriconazole,
amphotericin B, and micafungin was performed on all
isolates using the Clinical and Laboratory Standards
Institute (CLSI) broth microdilution (BMD) method,
according to document M27-A3; minimum inhibitory
concentrations (MICs) were determined after 24 h of incubation
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(Clinical Laboratory Standards Institute [CLSI], 2008). Species-
specific clinical breakpoints proposed by the CLSI document
M27-S4 were used for the categorical interpretation for
fluconazole and micafungin MICs (Clinical and Laboratory
Standards Institute [CLSI], 2012). In addition, the epidemiologic
cutoff values (ECVs) were used for the threshold for resistance to
voriconazole and amphotericin B, as the CLSI has not set clinical
breakpoints for these two antifungal agents against C. glabrata
(Pfaller and Diekema, 2012).Two reference strains, Candida
parapsilosis ATCC 22019 and Candida krusei ATCC 6258, were
included in each antifungal susceptibility test as quality control
isolates.
MLST
MLST was performed using a procedure described previously
(Dodgson et al., 2003). The six genes selected for MLST analysis
were FKS, LEU2, NMT1, TRP1, UGP1, and URA3. The reaction
products were analyzed using an ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems). The allele profiles of the strains
were defined according to the six MLST loci. Each unique allele
profile was designated as a ST, determined using the MLST
database.1
Sequence Analysis of the msh2 Gene
Candida glabrata genomic DNA was extracted as previously
described (Dodgson et al., 2003), using the DNeasy Mini kit
(Qiagen Inc., Valencia, CA, United States), and used as the
template for amplification of the full-length msh2 gene. Primers
used for amplification and sequencing of msh2 were as follows
(Healey et al., 2016b): for amplification, 5′-CGATGAGCCGATC
ACTTTAC-3′ (CgMSH2u273F) and 5′-ACTTATCGAGGCACT
CAGTC-3′ (CgMSH2d145R); for sequencing, 5′-ACCTAGCATC
TCTTGTTCAC-3′ (CgMSH2c846R), 5′-CCTGGTCAATCTCA
TACACC-3′ (CgMSH2c1626R), 5′-CCATGCAAGTCCAAAAC
CATC-3′ (CgMSH2c2340R), and 5′-ACTTATCGAGGCACTC
AGTC-3′ (CgMSH2d145R). Amplification conditions were as
follows: an initial denaturation step for 3 min at 95◦C, followed
by 29 cycles of denaturation for 40 s at 95◦C, annealing for 90 s at
56◦C, elongation for 3 min at 72◦C, and a final elongation step for
10 min at 72◦C. Polymerase chain reaction (PCR) products were
purified using a PCR purification kit (GeneAll Biotechnology,
Seoul, Korea) according to the manufacturer’s recommendations.
PCR products were sequenced using the abovementioned PCR
primer pairs. Sequencing of both strands was performed using
the ABI PRISM 3730XL Analyzer (Applied Biosystems, Foster
City, CA, United States). Nucleotide sequences were analyzed
using the MegAlign software package (DNAStar Inc., Madison,
WI, United States) and compared with that of the database strain,
CBS138/ XM_447585.
Clinical Data Analysis
Clinical information including demographics, clinical status
at positive culture, and therapy-related factors, and outcome
of fungemia were collected retrospectively from 185 available
patients with C. glabrata BSI (Kim et al., 2009; Choi et al.,
1http://www.mlst.net/
2016). Clinical status at positive culture examined within
30 days before the candidemia occurrence included prior
surgery, total parenteral nutrition use, prior antifungal exposure,
immunosuppressive therapy, and neutropenia (defined as an
absolute neutrophil count of 500/mm3). Severe sepsis, which
was recently termed “sepsis” after the Sepsis-3 definition, was
defined as life-threatening organ dysfunction caused by a
dysregulated host response to infection and organ dysfunction
identified as an acute change in total Sequential Organ Failure
Assessment (SOFA) score (≥ 2 points) following infection
(Singer et al., 2016). The “Candida score” was determined by
variables including total parenteral nutrition, surgery, multifocal
Candida colonization, and severe sepsis (Leon et al., 2006).
The age-adjusted Charlson comorbidity index (ACCI) was
calculated using the algorithm proposed by Charlson et al.,
in which 19 comorbid conditions are weighted and scored,
with additional points added for age (Charlson et al., 1987;
Hall et al., 2004). Patient outcome (survival or death) was
assessed as all-cause mortality at 7, 30, 60, 90, and 120 days
after the first positive blood culture result. This study was
approved by the Institutional Review Board of Chonnam
National University Hospital (IRB CNUH-2014-290). A waiver
of the requirement for informed consent was granted given
the retrospective nature of the project. Patient information
was anonymized and de-identified prior to the analysis, and
no information that could lead to patient identification was
used.
Statistical Analysis
Quantitative variables are expressed as means and standard
deviation, and categorical variables as counts and percentages.
Comparison of categorical variables between groups was
performed using the χ2 or Fisher’s exact t-test. The independent
t-test was used to compare continuous variables between two
groups, the Mann–Whitney U test to compare continuous
variables with non-normal distributions, and one-way analysis
of variance (ANOVA) to compare variables among more than
three groups, as appropriate (Jung et al., 2016). The predictive
factors for 30-day mortality were analyzed using univariate
and multivariate logistic regression analysis (Agresti, 2013).
Variables with p < 0.1 in univariate analyses were included in
multivariate regression models. The Cox proportional hazard
model was used to evaluate potential risk factors for 30-
day mortality by the hazard ratio (HR). The Kaplan–Meier
method was used to calculate 120-day survival probability
in subgroup analyses. All statistical analyses were performed
using SPSS software (ver. 18.0; SPSS Inc., Chicago, IL,
United States), and significance was determined at a level of
p< 0.05.
RESULTS
MLST and Antifungal Susceptibility
MLST results and the prevalence of FR among 209 BSI isolates of
C. glabrata from 209 patients of seven Korean hospitals (hospitals
A–G) spanning two time periods: September 2009 to August 2010
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TABLE 1 | Multilocus sequence typing (MLST) and fluconazole resistance (FR) status of 209 Candida glabrata bloodstream isolates from seven Korean hospitals.
Sequence type
(ST) by MLST
Total (%), all
periods
FR (%), all
periods
Period† No. of isolates (No. of FR isolates) in hospital Subtotal (%),
each period
Subtotal FR (%),
each period
A B C D E F G
7 100 (47.8) 9 (9.0) 1 16 12 (2) 2 3 3 3 (1) 8 47 (50.0) 3 (6.4)
2 23 (1) 9 (3) 4 6 (2) 3 4 4 53 (46.1) 6 (11.3)
3 47 (22.5) 4 (8.5) 1 6 1 1 3 1 3 1 16 (17.0)
2 9 (2) 9 (2) 5 2 6 31 (27.0) 4 (12.9)
22 12 (5.7) 1 2 2 4 (4.3)
2 2 1 2 3 8 (7.0)
10 9 (4.3) 1 1 2 1 1 5 (5.3)
2 1 3 4 (3.5)
55 5 (2.4) 1 (20.0) 1 1 1 1 3 (3.2)
2 2 (1) 2 (1.7) 1 (50.0)
2 4 (1.9) 2 (50.0) 1 1 2 (2) 3 (3.2) 2 (66.7)
2 1 1 (0.9)
6 4 (1.9) 1 1 1 2 (2.1)
2 2 2 (1.7)
26 4 (1.9) 1 2 2 (2.1)
2 1 1 2 (1.7)
12 2 (1.0) 1 1 1 (1.1)
2 1 1 (0.9)
59 2 (1.0) 1 2 2 (2.1)
2 0 (0.0)
Others‡ 20 (9.6) 1 3 3 1 2 9 (9.6)
2 5 2 2 1 1 11 (9.6)
Total 209 (100) 16 (7.7) 1 32 19 8 7 8 9 12 94 (100) 5 (5.3)
2 42 25 10 8 8 7 15 115 (100) 11 (9.6)
†Period 1: September 2009–August 2010; period 2: January 2014–December 2014. ‡Others include 20 STs, each derived from a single isolate.
(period 1; n = 94), and January to December 2014 (period 2;
n = 115) are shown in Table 1. Overall, 30 unique STs among
the 209 clinical isolates were obtained. A total of 191 isolates
belonged to the 12 previously described STs (2, 3, 6, 7, 10, 12,
19, 22, 26, 46, 55, and 59), whereas 18 isolates belonged to 18
new STs. Twenty STs were each derived from a single isolate,
and ten STs were shared by 189 isolates (90.4%). ST7 (100
isolates, 47.8%) was the most common type, followed by ST3 (47
isolates, 22.5%), ST22 (12 isolates, 5.7%), and ST10 (9 isolates,
4.3%). ST7 represented 50.0% (47/94) and 46.1% (53/115) of
all C. glabrata BSI isolates obtained during study periods 1 and
2, respectively, and ST3 represented 17.0% (16/94) and 27.0%
(31/115) of all C. glabrata BSI isolates obtained during study
periods 1 and 2, respectively. The major two ST types, ST7 and
ST3, were found in all 7 hospitals through the study periods,
however, the other STs were scattered in some hospitals. Overall,
two major STs (ST7 and ST3) comprised 70.3% (147/209) of all
C. glabrata BSI isolates obtained during the study periods. Of
the 209 isolates, 16 (7.7%) were resistant to both fluconazole
(MIC ≥ 64 µg/ml) and voriconazole (MIC > 0.5 µg/ml). All
isolates were susceptible to amphotericin B (≤ 2 µg/ml) and
micafungin (≤ 0.06 µg/ml). The FR rates were not significantly
different among ST7, ST3, and other minor ST isolates, at 9.0%
(9/100), 8.5% (4/47), and 4.8% (3/62), respectively. The FR rates
were 5.3% (5/94) and 9.6% (11/115) during periods 1 and 2,
respectively.
Mutations in msh2
Non-synonymous mutations in the mismatch repair gene (msh2
mutations) according to MLST genotype and fluconazole and
voriconazole susceptibilities are described in Table 2. All 16
FR isolates and one FS (MIC, 32 µg/ml) isolate were resistant
to voriconazole. Msh2 mutations occurred in 65.1% (136/209)
of the C. glabrata BSI isolates from Korean hospitals. Msh2
mutations were detected in 68.8% (11/16) of FR isolates and
67.4% (130/193) of fluconazole susceptible-dose dependent (FS)
isolates. Among the 189 BSI isolates that shared 10 STs (excluding
20 STs unique to a single isolate), isolates of the same ST
harbored identical msh2 mutations, with the exception of seven
isolates: ST7 (three isolates), and ST3 (four isolates) showed an
additional mutation compared with their ST strains. All 100
isolates of ST7 (nine FR and 91 FS) harbored the V239L mutation,
associated with prominent hypermutability, and three isolates
showed additional msh2 mutations (V63F, V615A, or G204A).
Among the 47 ST3 isolates, only four FS isolates harbored
E7K (two isolates), Y167N (one isolate), or S118N (one isolate)
mutations, and no non-synonymous mutations were found in
91.5% (43/47) of the ST3 isolates. All 12 ST22 isolates possessed
the E456D mutation and all 9 ST10 isolates possessed the
P208S/N890I mutation. No mutations were observed in any of
the isolates of ST55 (five isolates), ST6 (four isolates), ST26 (four
isolates), or ST59 (two isolates). Two isolates of ST12 harbored
the E456D mutation. Overall, the MSH2 sequence analysis
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TABLE 2 | Non-synonymous mutations in the mismatch repair gene (msh2 mutations) in 209 C. glabrata bloodstream isolates according to MLST genotye, fluconazole
and voriconazole susceptibilities.
MLST Msh2 mutation∗ No. of isolates§ Total
ST Allele profile† Fluconazole
susceptible-dose dependent
Fluconazole
resistant
Voriconazole
susceptible
Voriconazole
resistant
7 3-4-4-3-3-4 V239L 88 9 87 10 100
V63F, V239L 1 1
V239L, V615A 1 1
G204A, V239L 1 1
3 5-7-8-7-3-6 None 39 4 39 4 47
E7K 2 2
Y167N 1 1
S118N 1 1
22 7-5-6-3-1-8 E456D 12 12 12
10 8-4-3-5-1-2 P208S, N890I 9 9 9
55 3-6-22-2-3-9 None 4 1 4 1 5
2 1-2-2-1-1-1 V239L, A942T 2 2 2 2 4
6 2-5-7-5-1-2 None 4 4 4
26 7-4-3-4-1-8 None 4 4 4
12 7-5-6-12-1-8 E456D 2 2 2
59 7-13-17-9-3-19 None 2 2 2
Others‡ V239L 9 9 9
E456D 1 1 1
None 10 10 10
Total 193 16 192 17 209
†Allele profile for FKS-LEU2-NMT1-TRP1-UGP1-URA3.‡Others include 20 STs which were each derived from a single isolate. ∗The sequences of six non-synonymous
mutations within MSH2 gene (E7K, V63F, S118N, Y167N, G204A, and V615A) found only in Korean isolates have been deposited in GenBank with accession numbers
MH351625 to MH351627, and MH423282 to MH423284. § Fluconazole results were obtained by the CLSI clinical breakpoints (Clinical and Laboratory Standards Institute
[CLSI], 2012), while the ECV of 0.5 µg/ml was used for the threshold for voriconazole resistance, as the CLSI has not set clinical breakpoints for voriconazole against
C. glabrata (Pfaller and Diekema, 2012).
revealed that the majority of isolates harbored the V239L (112
isolates, 53.6%), followed by no mutation (69 isolates, 33.0%),
E456D (15 isolates, 7.2%), and P208S/N890I (9 isolates, 4.3%),
respectively. Msh2 mutations were found in 100% (100/100),
8.5% (4/47), and 59.7% (37/62) of ST7, ST3, and other isolates,
respectively.
Clinical Characteristics and Mortality
A total of 185 patients were assessed to obtain data to predict
clinical outcomes. Among all 185 patients, overall cumulative
mortality occurred in 19.5, 39.5, and 47.0% at 7, 30, and 60 days
after positive blood culture. Table 3 summarizes the clinical
characteristics of 185 patients infected with ST3, ST7, or the other
minor ST BSI strains of C. glabrata. There were no significant
differences among these three groups with respect to age, sex, or
clinical status at positive culture. However, significant differences
were found among the three groups in 30-day mortality rate
(43.3, 48.8, and 25.0% for ST7, ST3, and minor STs, respectively;
p = 0.035), and 60-day mortality rate (53.3% vs. 53.5% vs. 30.8%,
p = 0.022, respectively), respectively. There were no significant
differences among clinical characteristics between ST3 and ST7.
When two major ST strains (ST7 and ST3) and other minor
strains were considered, there were significant difference between
two groups in neutropenia (two major STs vs. the minor STs; 9.0%
vs. 0.0%, p = 0.025), 30-day mortality rate (two major STs vs. the
minor STs; 45.1% vs. 25.0%, p = 0.012), 60-day mortality rate (two
major STs vs. the minor STs; 53.4% vs. 30.8%, p = 0.006) and
120-day mortality rate (two major STs vs. the minor STs; 56.4%
vs. 36.5%, p = 0.015; Table 3).
Table 4 shows the results of univariate and multivariate
logistic regression analyses performed to identify risk factors
for 30-day mortality. Based on the full multivariate model,
the major STs (odd ratio [OR]: 4.058; 95% confidence interval
[CI]: 1.349−12.201; p = 0.013), severe sepsis (OR: 9.886; 95%
CI: 2.472−39.540; p = 0.001), and lack of antifungal therapy
(OR: 2.850; 95% CI: 1.026–7.918; p = 0.044) were independent
predictors of 30-day mortality. The adjusted Cox proportional
hazard model revealed that stains with the two major STs
(HR: 2.706; 95% CI: 1.236–5.921; p = 0.013) and severe sepsis
(HR: 4.577; 95% CI: 1.884–11.119; p = 0.001) were significantly
associated with 30-day mortality, in addition to lack of antifungal
therapy (HR: 3.164; 95% CI: 1.733–5.777: p< 0.001), respectively
(Figure 1). Kaplan–Meier survival analysis showed that the
differences in mortality between patients with two major STs
and those with other minor STs were sustained (p = 0.0067;
log-rank tests). Patients with the two major STs experienced
shorter survival than those with other minor STs (p = 0.0184 for
120-day survival; p = 0.0231 for 90-day survival; p = 0.0115 for
60-day survival; p = 0.0215 for 30-day survival; p = 0.0405 for
7-day survival; log-rank tests; Figure 2). There were no significant
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TABLE 3 | Clinical characteristics of C. glabrata bloodstream isolates belonging to two major STs (ST7 and ST3) and other minor STs.
Variables Two major MLST types Other minor STs
ST7 ST3 Total of two major STs
No. of patients 90 43 133 52
Demographics
Age, years, mean ± SD 68.2 ± 14.91 66.2 ± 14.22 67.5 ± 14.67 67.2 ± 12.23
Male, No. (%) 47 (52.2) 20 (46.5) 67 (50.4) 27 (51.9)
Clinical status at positive culture
Prior fungal therapy, No. (%) 12 (13.3) 8 (18.6) 20 (15.0) 3 (5.8)
Total parenteral nutrition, No. (%) 41 (45.6) 20 (46.5) 61 (45.9) 21 (40.4)
Prior surgery (1 months), No. (%) 24 (26.7) 9 (20.9) 33 (24.8) 13 (25.0)
Severe sepsis, No. (%) 46 (51.1) 20 (46.5) 66 (49.6) 27 (51.9)
Neutropenia (< 500 cell/mm3), No. (%) 7 (7.8) 5 (11.6) 12 (9.0)† 0 (0.0)
Immunosuppressive therapy, No. (%) 22 (24.4) 8 (18.6) 30 (22.6) 8 (15.4)
ICU admission, No. (%) 19 (21.1) 12 (27.9) 31 (23.3) 9 (17.3)
Urine catheter, No. (%) 54 (60.0) 26 (60.5) 80 (60.2) 30 (57.7)
CVC use, No. (%) 52 (57.8) 31 (72.1) 83 (62.4) 26 (50.0)
Candida score, mean ± SD 1.5 ± 0.91 1.3 ± 0.86 1.4 ± 0.90 1.5 ± 1.35
ACCI, mean ± SD 6.6 ± 3.10 7.3 ± 2.89 6.9 ± 3.04 6.0 ± 2.81
Therapy after positive culture
Antifungal therapy 64 (71.1) 28 (65.1) 92 (69.2) 33 (63.5)
Removal of CVC, No. (%) 40 (44.4) 26 (60.5) 66 (49.6) 24 (46.2)
Clinical outcome
7-day all-cause mortality, No. (%) 18 (20.0) 11 (25.6) 29 (21.8) 7 (13.5)
30-day all-cause mortality, No. (%) 39 (43.3) 21 (48.8) 60 (45.1)† 13 (25.0)
60-day all-cause mortality, No. (%) 48 (53.3) 23 (53.5) 71 (53.4)† 16 (30.8)
90-day all-cause mortality, No. (%) 50 (55.6) 24 (55.8) 74 (55.6)† 19 (36.5)
120-day all-cause mortality, No. (%) 51 (56.7) 24 (55.8) 75 (56.4)† 19 (36.5)
†p-value< 0.05, significant difference between two major STs (ST7 and ST3) vs. other minor STs. CVC, central venous catheter; ACCI, age-adjusted Charlson comorbidity
index.
differences in clinical characteristics, including mortality rate,
according to the msh2 mutation type.
DISCUSSION
To our knowledge, this is the first study to report that two major
ST (ST7 and ST3) strains, comprising 70.3% of all C. glabrata
BSI isolates from Korean hospitals, are linked to higher mortality
in candidemia patients. The rates of antifungal resistance were
not significantly different among ST7, ST3, and other strains.
Of the two major STs, ST7 isolates harbored the same V239L
substitution in msh2, which is associated with hypermutability,
whereas nearly all ST3 isolates lacked msh2 mutations. Overall,
we found that occurrences of most msh2 mutations were
associated with specific MLST genotypes, irrespective of FR. The
present study highlights that MLST genotypes are associated not
only with particular msh2 mutations but also with the prediction
of mortality in candidemia patients with C. glabrata.
To date, only a few studies have investigated the MLST
genotypes of BSI isolates of C. glabrata collected by multicenter
surveillance (Lott et al., 2010, 2012; Hou et al., 2017). MLST
of 230 BSI isolates in three United States cities showed that
three STs (ST3, ST16, and ST19) were the most abundant,
together comprising 51% of all BSI isolates (Lott et al., 2010).
The prevalence of ST16 among BSI isolates of C. glabrata in
Atlanta-area hospitals increased significantly between 1992 and
1993 (4%) and 2008 (40%). An increase was also observed for
ST3, from 19 to 28%, but the prevalence of ST19 did not change
(Lott et al., 2010). A recent study from China showed that ST7
and ST3 were the most common STs (68.0 and 9.0% of all 200
BSI isolates, respectively; Hou et al., 2017). In the present study,
ST7 and ST3 were the predominant genotypes (47.8 and 22.5% of
all BSI isolates, respectively) among 209 BSI isolates. During the
two study periods, the prevalence of ST7 remained unchanged at
4.5-year intervals (50.0 and 46.1%, respectively), but that of ST3
increased (17 and 27%, respectively), suggesting that ST3 strains
evolved for optimal adaptation to new environments as causative
agents of BSI in Korea. No ST16 strain was isolated in either of
two studies in China (Hou et al., 2017) or Korea (present study).
Collectively, our results support the notion that the major MLST
genotypes of C. glabrata BSI isolates vary both geographically and
over time.
Clinical characteristics of the specific MLST genotypes of
C. glabrata BSI isolates has not previously been reported. In
the present study, cumulative mortalities of C. glabrata BSI at
7 and 30 days after the first episode of candidemia were 19.5
and 39.5%, respectively, which is similar to previous reports
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TABLE 4 | Univariate and multivariate logistic regression analyses of prognostic factors for 30-day mortality.
Characteristic Survivors (N = 112) Non-survivors (N = 73) Univariate analysis Multivariate analysis†
p-value Odd ratio (95% CI) p-value
Demographics
Age, years, mean ± SD 66.8 ± 14.99 68.4 ± 12.34
Male, No. (%) 51 (45.5) 43 (58.9) 0.075 2.413 (0.934−6.229) 0.069
Clinical status at positive culture
Prior antifungal exposure, No. (%) 11 (9.8) 12 (16.4) 0.195
Intensive care unit admission, No. (%)‡ 17 (15.2) 23 (31.5) 0.02 1.238 (0.403−3.800) 0.71
Total parenteral nutrition, No. (%) 46 (41.1) 36 (49.3) 0.253
Immunosuppressive therapy, No. (%) 25 (22.3) 13 (17.8) 0.455
Neutropenia, No. (%) 5 (4.5) 7 (9.6) 0.172
Prior surgery, No. (%) 31 (27.7) 15 (20.5) 0.269
Severe sepsis, No. (%)‡ 41 (36.6) 52 (71.2) < 0.001 9.886 (2.472−39.540) 0.001
CVC use, No. (%) 66 (58.9) 43 (58.9) 0.97
Urine catheter, No. (%)‡ 60 (53.6) 50 (68.5) 0.036 1.973 (0.573−6.792) 0.281
Candida score, mean ± SD‡ 1.3 ± 0.85 1.7 ± 1.24 0.009 0.729 (0.359−1.480) 0.381
ACCI, mean ± SD‡ 6.3 ± 2.84 7.2 ± 3.16 0.045 1.053 (0.889−1.246) 0.551
Therapy after positive culture
Removal of CVC, No. (%) 52 (46.4) 38 (52.1) 0.246
Lack of antifungal therapy, No. (%)‡ 29 (25.9) 31 (42.5) 0.019 2.850 (1.026−7.918) 0.044
C. glabrata isolate
Major STs (ST 7 or ST 3)‡ 73 (65.2) 60 (82.2) 0.01 4.058 (1.349−12.201) 0.013
Fluconazole resistance 6 (5.4) 7 (9.6) 0.277
†Variables with p < 0.1 by univariate analysis were evaluated using multivariate analysis. ‡Variables with p < 0.05 between survivors and non-survivors. CVC, central
venous catheter; ACCI, age-adjusted Charlson comorbidity index.
(Lortholary et al., 2014; Ding et al., 2015). Notably, we found
a significant difference in the 30-day mortality of C. glabrata
candidemia due to the two major ST (ST3 or ST7) strains
and in that of candidemia due to other minor ST strains
(45.1% vs. 25.0%). There were no significant differences in all
clinical characteristics between ST3 and ST7. We could not find
significant differences in other clinical features between patients
with either of the two major STs or other minor STs, except
for neutropenia. Although neutropenia may have an impact on
the mortality of C. glabrata fungemia (Wu et al., 2017), only 12
patients (6.5%) had neutropenia in the present study. We found
the same results that two major STs were associated with higher
30-day mortality than other minor STs, even after we removed
the data for the 12 patients with neutropenia.
Multivariate logistic regression identified the two major STs,
severe sepsis, and lack of antifungal therapy as independent
variables associated with a higher 30-day mortality rate. The
adjusted Cox proportional hazard model also revealed that the
two major STs and severe sepsis were significantly associated with
30-day mortality, in addition to lack of antifungal therapy. Proper
administration of antifungal agents (Bassetti et al., 2017) or
therapeutic measures such as antifungal treatment within the first
48 h (Garnacho-Montero et al., 2017), severe sepsis and septic
shock (Puig-Asensio et al., 2014; Garnacho-Montero et al., 2017)
have been reported as variables independently associated with
30-day mortality of candidemia. However, candidemia due to the
two major ST strains of C. glabrata was more likely to be fatal than
candidemia due to other strains in our cohort. The Kaplan–Meier
survival analysis also showed that the differences in mortality
between the major STs and the other minor STs were sustained
from 30 to 120 days after positive blood culture. Although it is
difficult to establish that the death of a patient was attributable
solely to candidemia, a link between the presence of two ST
strains and increased mortality seems the likely explanation for
our data.
A recent study reported that msh2 mutations varied according
to MLST genotypes; however, only 48 clinical isolates were
tested (Healey et al., 2016a). In our work, we compared msh2
mutations by MLST genotype using 209 BSI isolates from
seven hospitals during a 2-year period, and demonstrated
that most isolates of the same ST harbored identical msh2
mutations. Among the 189 BSI isolates that shared 10 STs
(excluding 20 STs unique to a single isolate) in the present
study, isolates of the same ST harbored identical msh2
mutations, with the exception of nine isolates that showed
an additional mutation compared to their ST strains. In a
previous report, strains harboring V239L/A942T or V239L
in msh2 were identified in centers in the United States,
Switzerland, Qatar, and India, but the majority of strains isolated
from United States medical centers exhibited E231G/L269F or
P208S/N890I mutations (Healey et al., 2016a). In the present
study, the majority of isolates (53.6%) harbored V239L, followed
by no mutation (33.0%), E456D (7.2%), and P208S/N890I
(4.3%). Our data suggest that geographic differences in the
frequency of msh2 mutations in clinical C. glabrata isolates
(Healey et al., 2016b) may reflect differences in the distribution
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FIGURE 1 | Hazard ratios (HRs) for 30-day mortality according to various factors. Lines indicate HRs and their 95% confidence intervals (CIs) for all variables
suggested as prognostic factors for 30-day mortality by univariate analysis (p < 0.1) (Table 4). Asterisks indicate p < 0.05 in adjusted HRs. Abbreviations: Major
STs, major sequence types (ST7 or ST3) by multilocus sequence typing (MLST; ACCI, age-adjusted Charlson comorbidity index; ICU, intensive care unit.
FIGURE 2 | Survival analysis for candidemia patients. Patients with
bloodstream infections were grouped according to MLST type (ST3, ST7, or
Other STs) and censored at death or day 120. There was a significant
difference in mortality rate between the curves.
of the major MLSTs of C. glabrata among hospitals or geographic
locales.
It has been reported that msh2 mutations are more frequent
among FR (65%) and multidrug resistant (62%) C. glabrata
isolates than among FS isolates (52%) (Healey et al., 2016b).
However, among the 209 BSI isolates in the current study, the
frequency of msh2 mutations was similar between FS (67.4%,
130/193) and FR (68.8%, 11/16), which is consistent with the
findings of a recent study (Dellière et al., 2016). In the present
study, the rate of msh2 mutations was different among ST7
(100%), ST3 (8.5%), and other (58.1%) strains, but FR rates
did not differ significantly among ST7 (9.0%), ST3 (8.5%), and
other (4.8%) strains. It is possible that not all msh2 mutations
are equal and they may not all contribute to the acquisition of
fluconazole resistance. Notably, V239L and P208S/N890I, but not
E456D or E7K, were shown to confer partial loss of msh2 function
(Dellière et al., 2016; Healey et al., 2016b); how the other msh2
polymorphisms identified within our study influence phenotype
has yet to be determined. However, a more recent study has
shown the absence of azole or echinocandin resistance in C.
glabrata isolates in India despite background prevalence of strains
with defects in DNA mismatch repair pathway; albeit, isolates
were collected from patients with limited antifungal exposure.
Notably, 49% of tested strains in India contained partial loss of
msh2 mutation (Singh et al., 2018). Also, Healey et al. showed
that additional mechanisms of DNA repair, including other MMR
genes, and other cellular systems may influence the mutagenic
potential of C. glabrata strains (Dellière et al., 2016). Taken
together, these data suggest that msh2 mutations in C. glabrata
isolates occur independently of FR acquisition, and the msh2
mutation alone is not responsible for the acquisition or increased
prevalence of FR in specific STs.
Clinical outcomes of fungemia are dependent on the fungus
(virulence and susceptibility), host status (severity of the
underlying condition), and therapy (timing in relation to
infection stage, antifungal drug choice and dosing; Arendrup,
2013). In the present study, we found that two MLST genotypes
more frequently caused BSI infections than other genotypes in
Korea, and mortality at 30 days was higher for BSI with two
major ST strains than for BSI with other strains, suggesting
that the pathogenic potential of C. glabrata, with respect to
significant morbidity and mortality, may partly depend on the
MLST genotype. The most likely explanation for our results
is that the two major ST strains may be more virulent than
other minor ST strains in Korean patients. Therefore, some
of the virulence traits of C. glabrata which include growth
at 37◦C, high stress resistance, resistance to starvation, drug
resistance, high adherence or presence of several auxotrophies
(Gabaldon and Carrete, 2016) require investigation for strains of
Frontiers in Microbiology | www.frontiersin.org 8 July 2018 | Volume 9 | Article 1523
fmicb-09-01523 July 11, 2018 Time: 18:1 # 9
Byun et al. Genotypes and Outcome in C. glabrata Candidemia
major MLST genotypes. In addition, further study of major
MLST genotypes of C. glabrata BSI isolates and their expansion
over time will contribute significantly to our understanding of
incidence rates and patient outcomes of C. glabrata BSI, and their
antifungal resistance in particular geographic locations.
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